Hereditary breast cancer

Part I. Diagnosing hereditary breast cancer syndromes

Henry T. Lynch, Edibaldo Silva, Carrie Snyder, Jane F. Lynch

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Hereditary breast cancer (HBC) accounts for as much as 10% of the total BC burden. Most of these cases will be found to be due to a BRCA germline mutation. An estimated additional 15-20% of those affected with BC will have one or more first- and/or second-degree relatives with BC. Therefore, when these numbers are combined, familial BC risk accounts for approximately 20-25% of the total BC burden. However, because of the often limited information on family history in the etiologic assessment of BC, this may be an underestimate. Confounding factors include its phenotypic and genotypic heterogeneity, given the association of HBC with a plethora of differing cancer syndromes. Its most common occurrence is its association with ovarian cancer in the so-called hereditary breast-ovarian cancer syndrome due to BRCA1 and BRCA2 mutations. More rarely, it occurs in the Li-Fraumeni syndrome, caused by a p53 germline mutation, in which markedly early-onset BC is found in association with brain tumors, sarcomas, leukemia, lymphoma, malignant melanoma, and adrenal cortical carcinoma. Importantly, the age-adjusted incidence of BC in women in the United States fell sharply, by 6.7%, in 2003, when compared with the rate identified in 2002. We postulate that increasing knowledge about the genetics of BC may have partially contributed to the identification of high-risk patients who thereby may have benefited significantly from early diagnosis.

Original languageEnglish
Pages (from-to)3-13
Number of pages11
JournalBreast Journal
Volume14
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Hereditary Neoplastic Syndromes
Germ-Line Mutation
Hereditary Breast and Ovarian Cancer Syndrome
Li-Fraumeni Syndrome
Breast Neoplasms
Adrenocortical Carcinoma
Brain Neoplasms
Sarcoma
Ovarian Neoplasms
Early Diagnosis
Melanoma
Lymphoma
Leukemia
Mutation
Incidence
Neoplasms

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Oncology

Cite this

Hereditary breast cancer : Part I. Diagnosing hereditary breast cancer syndromes. / Lynch, Henry T.; Silva, Edibaldo; Snyder, Carrie; Lynch, Jane F.

In: Breast Journal, Vol. 14, No. 1, 01.2008, p. 3-13.

Research output: Contribution to journalArticle

Lynch, Henry T. ; Silva, Edibaldo ; Snyder, Carrie ; Lynch, Jane F. / Hereditary breast cancer : Part I. Diagnosing hereditary breast cancer syndromes. In: Breast Journal. 2008 ; Vol. 14, No. 1. pp. 3-13.
@article{67b13b8be67c4af78d7bf14d3d84ef46,
title = "Hereditary breast cancer: Part I. Diagnosing hereditary breast cancer syndromes",
abstract = "Hereditary breast cancer (HBC) accounts for as much as 10{\%} of the total BC burden. Most of these cases will be found to be due to a BRCA germline mutation. An estimated additional 15-20{\%} of those affected with BC will have one or more first- and/or second-degree relatives with BC. Therefore, when these numbers are combined, familial BC risk accounts for approximately 20-25{\%} of the total BC burden. However, because of the often limited information on family history in the etiologic assessment of BC, this may be an underestimate. Confounding factors include its phenotypic and genotypic heterogeneity, given the association of HBC with a plethora of differing cancer syndromes. Its most common occurrence is its association with ovarian cancer in the so-called hereditary breast-ovarian cancer syndrome due to BRCA1 and BRCA2 mutations. More rarely, it occurs in the Li-Fraumeni syndrome, caused by a p53 germline mutation, in which markedly early-onset BC is found in association with brain tumors, sarcomas, leukemia, lymphoma, malignant melanoma, and adrenal cortical carcinoma. Importantly, the age-adjusted incidence of BC in women in the United States fell sharply, by 6.7{\%}, in 2003, when compared with the rate identified in 2002. We postulate that increasing knowledge about the genetics of BC may have partially contributed to the identification of high-risk patients who thereby may have benefited significantly from early diagnosis.",
author = "Lynch, {Henry T.} and Edibaldo Silva and Carrie Snyder and Lynch, {Jane F.}",
year = "2008",
month = "1",
doi = "10.1111/j.1524-4741.2007.00515.x",
language = "English",
volume = "14",
pages = "3--13",
journal = "Breast Journal",
issn = "1075-122X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Hereditary breast cancer

T2 - Part I. Diagnosing hereditary breast cancer syndromes

AU - Lynch, Henry T.

AU - Silva, Edibaldo

AU - Snyder, Carrie

AU - Lynch, Jane F.

PY - 2008/1

Y1 - 2008/1

N2 - Hereditary breast cancer (HBC) accounts for as much as 10% of the total BC burden. Most of these cases will be found to be due to a BRCA germline mutation. An estimated additional 15-20% of those affected with BC will have one or more first- and/or second-degree relatives with BC. Therefore, when these numbers are combined, familial BC risk accounts for approximately 20-25% of the total BC burden. However, because of the often limited information on family history in the etiologic assessment of BC, this may be an underestimate. Confounding factors include its phenotypic and genotypic heterogeneity, given the association of HBC with a plethora of differing cancer syndromes. Its most common occurrence is its association with ovarian cancer in the so-called hereditary breast-ovarian cancer syndrome due to BRCA1 and BRCA2 mutations. More rarely, it occurs in the Li-Fraumeni syndrome, caused by a p53 germline mutation, in which markedly early-onset BC is found in association with brain tumors, sarcomas, leukemia, lymphoma, malignant melanoma, and adrenal cortical carcinoma. Importantly, the age-adjusted incidence of BC in women in the United States fell sharply, by 6.7%, in 2003, when compared with the rate identified in 2002. We postulate that increasing knowledge about the genetics of BC may have partially contributed to the identification of high-risk patients who thereby may have benefited significantly from early diagnosis.

AB - Hereditary breast cancer (HBC) accounts for as much as 10% of the total BC burden. Most of these cases will be found to be due to a BRCA germline mutation. An estimated additional 15-20% of those affected with BC will have one or more first- and/or second-degree relatives with BC. Therefore, when these numbers are combined, familial BC risk accounts for approximately 20-25% of the total BC burden. However, because of the often limited information on family history in the etiologic assessment of BC, this may be an underestimate. Confounding factors include its phenotypic and genotypic heterogeneity, given the association of HBC with a plethora of differing cancer syndromes. Its most common occurrence is its association with ovarian cancer in the so-called hereditary breast-ovarian cancer syndrome due to BRCA1 and BRCA2 mutations. More rarely, it occurs in the Li-Fraumeni syndrome, caused by a p53 germline mutation, in which markedly early-onset BC is found in association with brain tumors, sarcomas, leukemia, lymphoma, malignant melanoma, and adrenal cortical carcinoma. Importantly, the age-adjusted incidence of BC in women in the United States fell sharply, by 6.7%, in 2003, when compared with the rate identified in 2002. We postulate that increasing knowledge about the genetics of BC may have partially contributed to the identification of high-risk patients who thereby may have benefited significantly from early diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=37849039228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37849039228&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4741.2007.00515.x

DO - 10.1111/j.1524-4741.2007.00515.x

M3 - Article

VL - 14

SP - 3

EP - 13

JO - Breast Journal

JF - Breast Journal

SN - 1075-122X

IS - 1

ER -